• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy.

作者信息

Fontana Marianna, Gilbertson Janet, Verona Guglielmo, Riefolo Mattia, Slamova Ivana, Leone Ornella, Rowczenio Dorota, Botcher Nicola, Ioannou Adam, Patel Rishi K, Razvi Yousuf, Martinez-Naharro Ana, Whelan Carol J, Venneri Lucia, Duhlin Amanda, Canetti Diana, Ellmerich Stephan, Moon James C, Kellman Peter, Al-Shawi Raya, McCoy Laura, Simons J Paul, Hawkins Philip N, Gillmore Julian D

机构信息

University College London, London, United Kingdom.

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

出版信息

N Engl J Med. 2023 Jun 8;388(23):2199-2201. doi: 10.1056/NEJMc2304584.

DOI:10.1056/NEJMc2304584
PMID:37285532
Abstract
摘要

相似文献

1
Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy.抗体相关的转甲状腺素蛋白淀粉样变性相关心肌病的逆转
N Engl J Med. 2023 Jun 8;388(23):2199-2201. doi: 10.1056/NEJMc2304584.
2
Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.塔非酰胺：一种用于治疗野生型转甲状腺素蛋白淀粉样变性和遗传性转甲状腺素蛋白淀粉样变性心肌病的选择性转甲状腺素蛋白稳定剂。
Drugs Today (Barc). 2019 Dec;55(12):727-734. doi: 10.1358/dot.2019.55.12.3078389.
3
Therapy of ATTR Cardiac Amyloidosis: Current Indications.转甲状腺素蛋白心脏淀粉样变性的治疗：当前适应症
Curr Probl Cardiol. 2023 Feb;48(2):101487. doi: 10.1016/j.cpcardiol.2022.101487. Epub 2022 Nov 4.
4
Developing Therapy for Transthyretin Amyloidosis.开发转甲状腺素蛋白淀粉样变性症的治疗方法。
Am J Med. 2022 Apr;135 Suppl 1:S44-S48. doi: 10.1016/j.amjmed.2022.01.002. Epub 2022 Jan 22.
5
Targeted treatments of AL and ATTR amyloidosis.针对 AL 和 ATTR 淀粉样变性的靶向治疗。
Heart Fail Rev. 2022 Sep;27(5):1587-1603. doi: 10.1007/s10741-021-10180-z. Epub 2021 Nov 16.
6
Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.由淀粉样前体蛋白转甲状腺素蛋白V122I变体引起的散发性心脏淀粉样变性
Int Heart J. 2019 Nov 30;60(6):1441-1443. doi: 10.1536/ihj.19-134. Epub 2019 Oct 31.
7
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.抗心肌转甲状腺素蛋白抗体 NI006 用于清除心脏淀粉样变性的 1 期临床试验。
N Engl J Med. 2023 Jul 20;389(3):239-250. doi: 10.1056/NEJMoa2303765. Epub 2023 May 20.
8
Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.泰它西普在转甲状腺素蛋白淀粉样变性心肌病治疗中的应用：适应证和灰色地带。
Heart Fail Clin. 2024 Jul;20(3):333-341. doi: 10.1016/j.hfc.2024.03.007. Epub 2024 Apr 12.
9
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.口服治疗用于治疗转甲状腺素相关淀粉样心肌病。
Int J Mol Sci. 2022 Dec 18;23(24):16145. doi: 10.3390/ijms232416145.
10
Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment.特立氟胺治疗后 A97S 转甲状腺素蛋白心脏淀粉样变的心脏逆重构和功能障碍。
ESC Heart Fail. 2022 Dec;9(6):4335-4339. doi: 10.1002/ehf2.14165. Epub 2022 Sep 20.

引用本文的文献

1
Transthyretin Amyloid Cardiomyopathy Treatment: An Updated Review.转甲状腺素蛋白淀粉样心肌病的治疗：最新综述
J Clin Med. 2025 Aug 28;14(17):6089. doi: 10.3390/jcm14176089.
2
Utilization rates and determinants of PYP and CMR among patients with unexplained left ventricular hypertrophy on echocardiography.超声心动图显示原因不明的左心室肥厚患者中PYP和CMR的利用率及决定因素。
Int J Cardiol. 2025 Nov 1;438:133562. doi: 10.1016/j.ijcard.2025.133562. Epub 2025 Jun 25.
3
Exploring the Histopathological Features of Thrombus-Associated Localized Amyloid Deposition: Comprehensive Analysis Employing Immunohistochemistry and Proteomics.
探索血栓相关局部淀粉样沉积的组织病理学特征：采用免疫组织化学和蛋白质组学的综合分析
Int J Mol Sci. 2025 May 8;26(10):4505. doi: 10.3390/ijms26104505.
4
Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going.转甲状腺素蛋白淀粉样变心肌病的药物治疗：现状与展望
J Clin Med. 2025 May 16;14(10):3481. doi: 10.3390/jcm14103481.
5
Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy.转甲状腺素蛋白淀粉样心肌病的当前治疗格局
JACC Heart Fail. 2025 May;13(5):685-694. doi: 10.1016/j.jchf.2025.03.017.
6
Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis.在转甲状腺素蛋白淀粉样变性心肌病3期APOLLO - B研究的巴西亚组人群中进行的帕替西兰治疗：事后分析。
Arq Bras Cardiol. 2025 Mar;122(4):e20240568. doi: 10.36660/abc.20240568.
7
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions.心脏淀粉样变性的病因治疗：治疗标准与未来方向
Curr Heart Fail Rep. 2025 Apr 15;22(1):16. doi: 10.1007/s11897-025-00701-4.
8
Advancements in Cardiac Amyloidosis Treatment.心脏淀粉样变性治疗的进展
Biomedicines. 2024 Dec 31;13(1):79. doi: 10.3390/biomedicines13010079.
9
The revolution in pharmacotherapy: from herbs to pills, moulds, antibodies to genetic tools.药物治疗的革命：从草药到药丸、霉菌、抗体再到基因工具。
Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):109-111. doi: 10.1093/ehjcvp/pvae098.
10
The Last Decade in Cardiac Amyloidosis: Advances in Understanding Pathophysiology, Diagnosis and Quantification, Prognosis, Treatment Strategies, and Monitoring Response.心脏淀粉样变性的过去十年：在病理生理学理解、诊断与定量、预后、治疗策略及监测反应方面的进展
JACC Cardiovasc Imaging. 2025 Apr;18(4):478-499. doi: 10.1016/j.jcmg.2024.10.011. Epub 2025 Jan 8.